Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
Continued commercial and strategic execution delivers sequential core revenue growth of 4% – 9% to $26   million – $27 million in Q4 2022 for full year total of approximately $94 million – $95 million Business restructuring and SBS program on track to deliver over 20% reduction in operating
View HTML
Toggle Summary Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer
Former Danaher Executive Further Strengthens Senior Management Team SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of
View HTML
Toggle Summary Standard BioTools Authorizes up to $20 Million of Share Repurchases
SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that its board of directors has authorized the repurchase of up to $20 million of shares of
View HTML
Toggle Summary Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Nov. 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of November 20, 2022 , under the
View HTML
Toggle Summary Standard BioTools Announces Third Quarter 2022 Financial Results
Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0 million net on an annualized basis Reiterate stated goal of 700 to 1000 basis point non-GAAP product and
View HTML
Toggle Summary Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems
Seamlessly linking the Standard BioTools portfolio of Imaging Mass Cytometry (IMC) systems with Visiopharm AI-driven software for phenotyping cells in high-plex imaging SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
View HTML
Toggle Summary Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022,
View HTML
Toggle Summary Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China
SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products
View HTML
Toggle Summary Standard BioTools Announces Collaboration Agreement With Visikol to Offer Multiplex Imaging Mass Cytometry Services
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Visikol® for service offerings using Imaging Mass Cytometry™. SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needs SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human
View HTML